Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > SNTI Senti Biosciences > Detailed Quotes

SNTI Senti Biosciences

Watchlist
1.783
-0.047-2.57%
Close  01/27 16:00 ET
1.820
+0.037+2.09%
Post Mkt Price 01/27 17:29 ET
High
2.110
Open
1.870
Turnover
855.99K
Low
1.710
Pre Close
1.830
Volume
448.53K
Market Cap
78.18M
P/E(TTM)
Loss
52wk High
10.000
Shares
43.86M
P/E(Static)
Loss
52wk Low
1.200
Float Cap
45.91M
Bid/Ask %
33.33%
Historical High
10.540
Shs Float
25.76M
Volume Ratio
6.58
Historical Low
1.200
Dividend TTM
--
Div Yield TTM
--
P/B
0.56
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.74%
Amplitude
21.83%
Avg Price
1.908
Lot Size
1
Float Cap
45.91M
Bid/Ask %
33.33%
Historical High
10.540
Shs Float
25.76M
Volume Ratio
6.58
Historical Low
1.200
Dividend TTM
--
P/B
0.56
Dividend LFY
--
Turnover Ratio
1.74%
Amplitude
21.83%
Avg Price
1.908
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Senti Biosciences, Inc. It was incorporated in Delaware on March 1, 2021. The company aims to design genetic circuits to improve the intelligence of cells and gene therapy to improve its effectiveness, accuracy and persistence in the treatment of a wide range of diseases that cannot be solved by traditional drugs. The company's synthetic biology platform uses ready-made chimeric antigen receptor natural killer cells and is equipped with these genetic circuit technologies for particularly challenging liquid and solid tumor indications. The company's leading projects include SENTI-202 and SENTI-301. SENTI-202 is a logic-gated or + non-ready-made CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells while preserving healthy bone marrow. SENTI-301 is an off-the-shelf CAR-NK cell therapy for the treatment of hepatocellular carcinoma. The company has also demonstrated the breadth of its genetic circuits in ways other than oncology and diseases, and has partnered with Spark and BlueRock to advance these capabilities.
CEO: Dr. Timothy Lu, M.D.,PhD
Market: NASDAQ
Listing Date: 05/26/2021
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist